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The successful treatment of severe and chronic pain remains a primary goal of the physician and for this purpose clinicians continue to rely on extracts prepared from the opium poppy. Unfortunately morphine, the most important of the analgesic opiates, produces several undesirable side effects including respiratory depression, constipation, the development of tolerance and physical dependence. Consequently, a considerable effort has been made over the years to identify non-opiate means for controlling pain.
One of the most exciting developments in pain management came almost 20 years ago, with the demonstration that relief could be achieved by the electrical stimulation of discrete midbrain regions, in particular the periaqueductal gray and the periventricular hypothalamus. 25 49 These findings lent support to the concept that in the central nervous system there exists specific circuitry that modulates not only senses but also painful stimuli. It is generally accepted that these circuits have supraspinal and spinal components whose neurones communicate with one another via neurotransmitters, which include the biogenic amines (dopamine, norepinephrine and serotonin) and the opioid peptides (met-and leu-enkephalin, ␤-endorphin and dynorphin).
These neurotransmitters all directly influence neuronal physiology by first activating cell surface proteins referred to as receptors. The noncovalent interaction between a neurotransmitter, or ligand, and its cognate receptor causes a conformational change in the receptor molecule. This change constitutes a signal that can then be detected on the intracellular face of the cell by a complex of GTP binding proteins, or simply G proteins, that interact with second messenger systems to modulate enzyme activity (for example, adenylyl cyclase and protein kinase C), ion-channel conductance (potassium and calcium) and gene expression. 24 Although excellent targets for pharmacological manipulation, the opiate receptors are difficult proteins to work with biochemically because they are typically found in low concentration and they are labile, losing their activity upon purification away from a lipid environment. Cloning of the delta opioid receptor was therefore hailed as a major breakthrough when the work was published in 1992, and resulted in a burst of molecular studies to identify and express related receptors. 15 30 (Br. J. Anaesth. 1998; 81: [29] [30] [31] [32] [33] [34] [35] [36] [37] Keywords: pain; analgesics, opioid; orphan receptor; orphanin
Discovery of the opioid-like orphan receptor
The use of nucleic acid probes based on the delta opioid receptor resulted in the cloning of the mu and kappa opioid receptors, 10 38 as well as a new sequence that encoded a novel putative G protein-coupled receptor. 6 9 40 61 Although the deduced amino acid sequence of this new receptor is approximately 65% identical to the three bona fide opioid receptors, when expressed in tissue culture cells it fails to bind opioid ligands with high affinity. Hence this receptor came to be known as the opioid-like orphan receptor.
Distribution of the orphan receptor in the rat central nervous system
Localization studies performed in the rat have revealed that the receptor's mRNA and protein are widely distributed throughout the central nervous system. 6 40 66 Supraspinally its mRNA appears to be particularly dense in the cortex, hippocampus, hypothalamus, periaqueductal gray, dorsal raphe, and locus coeruleus (figs 1F, 2B and 2D). Although the presence of the orphan receptor's mRNA in these brain regions is similar to that reported for the opioid receptor mRNAs (reviewed in reference 36), in other areas there are striking differences. The most frequently noted of these is the caudate putamen, where mRNA encoding all three opioid receptors is easily detected but the orphan receptor's mRNA does not appear to be expressed (figs 1B and 1D).
Orphan receptor mRNA is expressed throughout the length of the spinal cord (figs 3B, 3D and 3E). In the cervical segments orphan receptor mRNA is most abundant in the superficial layers of the dorsal horn corresponding to laminae I and II (substantia gelatinosa) as well as lamina X, a distribution similar to that of the opioid receptors. 36 This distribution of orphan receptor mRNA suggests that, similar to the opioid receptors, its activation at this level of the cord could modulate nociceptive processing.
The distribution of the receptor's mRNA in the cervical cord is maintained more caudally in the thoracic cord. Essentially no labelling of receptor mRNA is seen in the intermediolateral nucleus, which contains preganglionic sympathetic neurones that are primarily involved in autonomic control (reviewed in reference 18). Changes in the distribution of orphan receptor mRNA begin to appear in TRISTAN segments of the lumbar cord where, in addition to labelling the superficial layers of the dorsal horn, a significant amount of receptor mRNA is scattered throughout lamina VII of the ventral horn ( fig. 3F ). Some of these neurones project to the cerebellum, whereas others project to the brainstem reticular formation and to the thalamus. 28 29 64 On the sole basis of anatomical considerations it seems likely that the activation of orphan receptors expressed in these neurones could influence somatomotor processing, including nociception.
Discovery of the endogenous ligand for the opioid-like orphan receptor
Confronted with the challenge of identifying the orphan receptor's endogenous ligand, Reinscheid and colleagues 48 sought clues in the structure of the receptor and the anatomical distribution of its mRNA. On the basis of the deduced amino acid sequence of the orphan receptor's putative extracellular domains, it was predicted that the endogenous ligand would be a positively charged peptide similar in mass and charge to dynorphin. Furthermore, as the receptor's putative intracellular domains are extensively homologous with those of the opioid receptors, this suggested that when activated, the orphan receptor would also couple to the inhibition of cAMP production.
The next step was to identify a brain region from which to extract and purify the orphan receptor's endogenous ligand. For this the receptor in-situ hybridization data proved invaluable. The two areas where the orphan receptor mRNA is most discretely and densely expressed in brain are the hypothalamus and the locus coeruleus. Reinscheid and colleagues chose the hypothalamus as their starting material because of its size and connectivity. Meunier and Figure 1 Distribution of prepro-orphanin FQ mRNA (A, C and E) and orphanin FQ receptor mRNA in adult rat forebrain (B, D and F). All in-situ hybridization was performed as described elsewhere, 12 using radiolabelled rat cDNA probes corresponding to 244 bp for prepro-OFQ and 309 bp for OFQR. Under darkfield illumination, zones of hybridization appear white. Sense probes, used as controls in these experiments, showed no detectable staining (data not shown). Arc:arcuate nucleus of the hypothalamus; AMPO:anterior medial preoptic nucleus; BSTLD:bed nucleus of stria terminalis, dorsolateral division; BSTMP:bed nucleus of stria terminals, medial posterior division; CA:central amygdala; CPu:caudate putamen; GP:globus pallidus; HIP:hippocampus; LSD:dorsolateral septal nucleus; LSV:ventrolateral septum; MA:medial amygdala; MH:medial habenula; MnPO:median preoptic nucleus; MPOA:medial preoptic area; ox:optic chiasm; RT:reticular thalamic nucleus; VMH:ventral medial hypothalamus. colleagues 37 successfully purified the identical peptide from the extract of 20 rat brains.
After ultrafiltration and chromatography of porcine hypothalamic extracts, the resulting fractions were evaluated for their ability to activate the orphan receptor in an in vitro bioassay. For this purpose two Chinese hamster ovary (CHO) cell lines were used: one that stably expresses the orphan receptor and one that does not. To evaluate a particular fraction of extract both cell lines would be treated with the fraction along with forskolin, an agent that stimulates the production of cAMP. Those fractions that inhibited the forskolinstimulated production of cAMP in cells expressing the receptor, but failed to inhibit cAMP production in the cells lacking receptor, were collected and subjected to reversed-phase high-performance liquid chromatography. Bioassay of these fractions identified a single peak of activity. The microsequence of this heptadecapeptide peptide is: Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-LysSer-Ala-Arg-Lys-Leu-Ala-Asn-Gln -a sequence that is strikingly similar to that of dynorphin. 19 To confirm that bioactivity resided in this sequence a synthetic peptide was prepared. The synthetic peptide potently and dose-dependently inhibited cAMP production in only those CHO cells expressing the orphan receptor. When used in pharmacological studies the peptide demonstrated normal binding kinetics to its cognate receptor and little cross-reactivity with the mu, delta or kappa opioid receptors. Reinscheid and colleagues named this peptide orphanin FQ-orphanin because its receptor had been known as the orphan receptor; FQ represents the N-terminal (phenylalanine, abbreviated F) and Cterminal (glutamine, abbreviated Q) residues of the peptide. Meunier and colleagues refer to the identical peptide they purified from rat brain as nociceptin.
Orphanin FQ is contained within a precursor protein
The structural similarity between OFQ and the opioid peptide dynorphin suggested that OFQ may also be synthesized as part of a precursor molecule that is subsequently processed. Efforts to identify a polypeptide that contained OFQ eventually led to the cloning of a cDNA prepared from rat brain mRNA that encodes a protein of 181 amino acids. 41 45 Orphanin's 17 amino acids are flanked by pairs of basic amino acids, known target sequences for subtilisin-like endopeptidases. 52 In the literature this precursor protein is referred to as both prepro-orphanin FQ (ppOFQ) and prepro-nociceptin.
The ppOFQ contains several peptides, in addition to OFQ, that are flanked by dibasic cleavage sites, an organization that is similar to that of prepro-dynorphin and pro-opiomelanocortin. Coincidentally, the peptide immediately following the C-terminal, dibasic amino acids of orphanin FQ, is another 17-amino-acid peptide that could also be correctly referred to as "orphanin FQ". If this peptide is found to have biological activity, it may become necessary to discriminate between the two, referring to OFQ/nociceptin as the alpha form and the other peptide as beta-OFQ/nociceptin.
The complex organization of prepro-OFQ suggests that the co-ordinated expression of OFQ and the other potentially bioactive peptides contained within it has conferred a selective survival advantage on the organism. Determining the functions that these potential prepro-OFQ progeny serve in vivo is currently an area of great interest.
Expression of prepro-orphanin FQ in the rat central nervous system
In addition to revealing that OFQ is processed from a precursor polypeptide, the cloning of the rat ppOFQ cDNA has provided valuable in-situ hybridization probes. With these, the detailed mapping of ppOFQ expression throughout the central nervous system has begun in an effort to better understand the peptide's functions in the central nervous system. 26 41 45 66 THE TELENCEPHALON Of the relatively little ppOFQ mRNA expressed in the rat cerebral cortex, the density of hybridization is greater in the superficial rather than deeper layers ( fig. 1E ). This expression pattern appears to be uniform along the rostral-caudal axis of the cortex. In this context, it is worth noting that OFQ has been reported to decrease glutamate release within cerebrocortical slices. 43 In the medial and central divisions of the amygdala, the lateral ventral and lateral dorsal septal nuclei, the anterior and medial posterior divisions of the bed nucleus of the stria terminalis (BST) and the medial preoptic area (POA), the expression of ppOFQ mRNA is dense (fig1). The amygdala and POA have reciprocal connections with the BST, as do the ventral tegmental area, locus coeruleus, dorsal raphe and raphe magnus. On the basis of these findings one role of OFQ, or the other peptides processed from ppOFQ, or both, may be to regulate and co-ordinate the firing of the major monoaminergic nuclei, thereby linking vigilance with the emotional and motivational states of the animal. It may prove informative to explore the possibility that OFQ circuits involving the BST may have some bearing on opiate dependence and withdrawal.
The POA, BST and amygdala are sexually dimorphic areas and as such are subject to regulation by sex hormones (reviewed in reference 51). The finding that both the ppOFQ and receptor mRNAs are intensely expressed in these areas (figs 1A and 1C) suggests a possible role for the OFQ system in the expression of sexually dimorphic behavioural responses, including perhaps responsiveness to opiates. It has also been recently reported that OFQ stimulates lordosis in female rats (reviewed in reference 67).
In the hippocampus ppOFQ probes produced moderate labelling of CA1, CA2 and CA3 hippocampal neurones but the signal was considerably weaker in neurones of the dentate gyrus ( fig.1E ). This expression pattern suggests a role for the OFQ system in learning and memory, and rats have been reported to have impaired spatial learning in the Morris water task, without decreased swimming performance, after injection of OFQ into the CA3 region of the dorsal hippocampus. 50 In the rat striatum, a ppOFQ probe lightly labelled the ventral pallidum and globus pallidus while, similar to the receptor, the caudate putamen and nucleus accumbens were conspicuously devoid of ppOFQ mRNA (figs 1A and 1C).
THE DIENCEPHALON
The expression of ppOFQ mRNA is dense in several structures of the diencephalon, including the subparafascicular (data not shown) and reticular thalamic nucleus (RT, fig. 1E ). The RT is interesting because it has reciprocal connections with most, if not all, of the other thalamic nuclei, and is responsible for a rhythmic modulation of corticothalamic neuronal electrical activity, which has been found to be correlated with the animal's level of vigilance. 54 The output of the RT is inhibitory and most of its neurones, at least in rat, are GABAergic. Therefore, future studies might usefully explore the effect of OFQ on the discharge rates of RT neurones and cortical electroencephalogram activity during somnolence and waking states.
Other thalamic nuclei expressing ppOFQ mRNA include the paratenial and central medial nuclei, which were moderately labelled (our unpublished results).The ventral lateral geniculate and intergeniculate leaflet displayed moderate staining while the dorsal lateral and medial geniculate appeared to be negative for ppOFQ (our unpublished results) as were the habenula, the ventrolateral, ventromedial and paraventricular thalamic nuclei ( fig. 1E) .
In the hypothalamus, dense expression of ppOFQ was detected in the arcuate nucleus, the zona incerta and anterior hypothalamic area (figs 1C and 1E, and unpublished results). Moderate expression was detected in the paraventricular nucleus, the dorsomedial nucleus and the lateral hypothalamic area. Conspicuously lacking ppOFQ mRNA were the ventral medial nucleus of the hypothalamus (VMH) ( fig.1E) , the suprachiasmatic and supraoptic nuclei (data not shown). The mammillary nuclei and the pituitary were also negative with respect to detectable ppOFQ expression (data not shown).
The relatively high level of OFQ receptor mRNA detected in the hypothalamus by in-situ hybridization figured importantly in the successful purification of OFQ. 48 Indeed, as measured by a recently developed radioimmunoassay, the concentration of OFQ peptide is highest in the rat hypothalamus. 47 This corre-lates well with the heavy expression of OFQ receptor mRNA in the arcuate nucleus, VMH and the paraventricular nucleus.
As the VMH is thought to be involved in reproductive behaviour it is possible that OFQ originating in other sexually important areas such as the BST may participate in regulating output from the VMH. The VMH is also recognized as an important area that may regulate feeding behaviour, a hypothesis that has received support from the demonstration that OFQ injected into the VMH stimulated feeding in sated rats. 46 55 The paraventricular nucleus of the hypothalamus is an important source of corticotropin-releasing hormone, which is involved in the regulation of the hypothalamic-pituitary-adrenocortical (HPA) stress axis. 20 Afferents to the paraventricular nucleus include those originating in the lateral septum, the BST and the POA (reviewed in reference 23). These areas are thought to be involved in the production of fear and anxiety, and given that ppOFQ mRNA is heavily expressed in these projecting areas this peptide may well be a new modulator of the HPA axis.
The abundant expression of ppOFQ mRNA in the arcuate nucleus raises several interesting possibilities, given the complex nature of its connections. It has been demonstrated by Wagner et al 60 that OFQ receptors are functional in GnRH-positive neurones of the arcuate nucleus, suggesting that OFQ may modulate the pulsatile release of this important reproductive hormone. Wagner and colleagues have also demonstrated the presence of functional OFQ receptors on tyrosine-hydroxylase-positive and ␤-endorphinpositive neurones in the arcuate nucleus. Therefore, it is likely that OFQ affects dopamine neurones that influence the pituitary and ultimately prolactin secretion as well as opioid neurones that project throughout the brain.
THE MESENCEPHALON
In the midbrain ppOFQ mRNA is densely to moderately expressed in the periaqueductal grey (PAG) and moderately expressed in the superficial gray layer of the superior colliculus, whereas all layers of the inferior colliculus were lightly labelled ( fig. 2A) , as was the ventral tegmental area and substantia nigra pars compacta (data not shown). No ppOFQ expression was detected in the interpeduncular nuclei, the substantia nigra or the red nucleus (data not shown).
In addition to its role in various behaviours, the PAG is widely recognized as an important area of the brain in terms of nociceptive processing. The basis for this is, in part, the ability of electrical stimulation of the PAG to produce analgesia in animals and relieve severe pain in humans, and the realization that opioids can produce profound analgesia when administered into the PAG. 25 Because of the complexity of the PAG it has been difficult to map out an analgesia circuit. However, much work indicates that the PAG receives innervation from the hypothalamus, forebrain and ascending nociceptors from laminae I and V of the dorsal horn. 3 Some PAG neurones project to the intralaminar nuclei of the thalamus and to the hypothalamus. 14 This innervation has important implications for the integration of painful sensations and emotional behaviour. The PAG also innervates the locus coeruleus and the raphe magnus. These areas are known to possess substantial projections to the dorsal horn of the spinal cord where they can inhibit the transmission of incoming nociceptive information within the substantia gelatinosa of the dorsal horn (reviewed in reference 2). Consequently, the dense expression of both ppOFQ and OFQ receptor mRNAs throughout the PAG suggests a role in modulating nociception, which is supported by several recently published behavioural and electrophysiological studies.
THE PONS, MEDULLA AND CEREBELLUM
The rostral periolivary region and the medioventral, lateroventral and superior periolivary nuclei in the brainstem all displayed dense expression of the ppOFQ mRNA, as did the posterodorsal tegmental nucleus and the prepositus hypoglossi ( fig. 2) . The raphe magnus and locus coeruleus, nucleus of the solitary tract, interpolar spinal trigeminal nucleus, lateral lemniscus, and pedunculopontine and microcellular tegmental nuclei all demonstrated moderate labelling ( fig. 2 , unpublished results, and references previously listed). No ppOFQ mRNA was detected in the nucleus paragigantocellularis, dorsal raphe, or pontine, vestibular or cochlear nuclei. In the cerebellum only the medial cerebellar nucleus appeared to express ppOFQ mRNA.
The dense labelling of the periolivary region by ppOFQ probes suggests that the peptide may be important in regulating the auditory system. It is notable that mice deficient in OFQ receptors have a substantially reduced ability to adapt their auditory brainstem response upon exposure to intense sound. 44 The ppOFQ mRNA-positive neurons in the periolivary region project to important relay nuclei in the auditory system, which express OFQ receptor mRNA. The most important of these are the medial vestibular nucleus and the dorsal and lateral cochlear nuclei (data not shown). It remains to be determined whether OFQ exerts its effects on the auditory system via these nuclei or perhaps by acting directly on the hair cells of the cochlea, as ppOFQ mRNA is expressed in areas where some of the neurones project directly to the outer hair cells. 5 The locus coeruleus, the major noradrenergic nucleus in brain, displays high levels of OFQ receptor mRNA ( fig. 2D ) and protein. 1 A high level of expression has also been detected in the prepositus hypoglossi ( fig. 2E) , one of the two major afferents to the locus coeruleus. The other, nucleus paragigantocellularis, was negative for ppOFQ mRNA (data not shown). Therefore, on the sole basis of in-situ hybridization data, it seems likely that OFQ will be found to be a major modulator of locus coeruleus output in vivo. OFQ has been shown to potently hyperpolarize neurones in the locus coeruleus (see below). As the locus coeruleus is important for determining the arousal state of the animal, it is anticipated that OFQ may have sedative effects.
Expression of ppOFQ mRNA in the spinal cord
The expression pattern of ppOFQ mRNA has also been examined in the cervical, thoracic and lumbar segments of the rat spinal cord. While some diffuse signal was detected centrally in all segments exam-ined, the most intense hybridization to ppOFQ mRNA was confined to the superficial layers of the dorsal horn corresponding to laminae I and II ( fig.  3) . In cervical sections faint hybridization corresponding to either ppOFQ or the OFQ receptor was detected in lamina V, although some signal can be seen in lamina X. In more caudal regions of the cord hybridization to ppOFQ transcripts were seen in the superficial layers of the dorsal horn, lamina V, as well as scattered cells in lamina VII of the ventral horn ( fig. 3E ). Essentially no labelling was seen in the intermediolateral zone, the area in which preganglionic sympathetic efferents are concentrated.
It has been reported that the activity of superficial dorsal horn neurones is inhibited by OFQ. 16 35 53 62 Most primary nociceptive afferents terminate in laminae II and V. 8 Many neurones in these regions are nociceptive and project rostrally to the reticular formation, thalamus and other parts of the forebrain. The dense expression of ppOFQ mRNA, as well as its receptor mRNA, in areas of the dorsal horn that are known to be involved in the transmission of noxious information strongly suggests a role for the OFQ system in modulating nociceptive transmission in the cord. It is not yet known whether the spinal neurones expressing OFQ project rostrally. However, the anatomical observation that little OFQ receptor mRNA or protein are seen in the ventral basal and posterior thalamus argues against expression in spinothalamic neurones (our unpublished results and reference 1). Therefore the neurones expressing OFQ in the dorsal horn are likely to be interneurones.
Electrophysiological actions of OFQ
Among the first studies to be conducted with synthetic OFQ peptide involved electrophysiological recording from slices of rat brain. In these initial experiments locus coeruleus neurones dose-dependently responded to the peptide with a large outward current. It was later shown that this current is carried by potassium ions flowing through inwardly rectifying potassium channels, the net effect of which is hyperpolarization. 11 In addition to locus coeruleus neurones, this finding has been extended to neurones in the dorsal raphe, 58 PAG 59 and hippocampal pyra- midal cells. 27 In studies involving hippocampal neurones it has been demonstrated that activated OFQ receptors also couple to calcium channels of the N1, L and P/Q type. 32 Therefore, at the level of cellular physiology, the consequences of activating the OFQ receptor are similar, if not identical, to the activation of the opioid receptors.
Actions of OFQ in algesiometric assays
Once it had been demonstrated pharmacologically and biochemically that the synthetic OFQ peptide can activate receptors that are heterologously expressed in cultured cells as well as tissue slices, the next important question became: what does it do in the whole animal? Opioids can produce analgesia by their activation of supraspinal as well as spinal receptors. As in-situ hybridization studies indicated that the OFQ receptor mRNA is expressed in both the brain and the spinal cord of rodents it was necessary to evaluate OFQ's actions both supraspinally and spinally. Although initial speculation favoured the possibility that OFQ would produce some degree of analgesia when administered in vivo, the story has proven to be more complex.
Supraspinal actions of OFQ
The fact that the OFQ peptide is rather large and positively charged at neutral pH suggests that it will not cross the blood-brain barrier easily, and as a consequence must be delivered directly into the brains of anaesthetized mice by intracerebroventricular injection (i.c.v.). In behavioural assays of nociceptive sensitivity, OFQ administered by i.c.v. has been shown to antagonize the analgesic effects of stress, 39 morphine 39 56 and electroacupuncture. 57 The i.c.v. injection procedure is stressful enough to produce an opioid-mediated analgesia that can be detected by choosing a sensitive measure of nociception such as the abdominal constriction assay. When this assay was used by Mogil and colleagues 39 the i.c.v. injection procedure produced a quantifiable, opioid-mediated analgesia in Swiss-Webster mice that could be reversed by the opioid antagonist naloxone. Unexpectedly, in this assay OFQ failed to potentiate analgesia but rather dose-dependently reversed it.
Initial reports that OFQ produced hyperalgesia 37 48 must be viewed with caution in light of the peptide's reversal of stress-induced analgesia. It is notable that Mogil and colleagues compared the response of an animal to the noxious stimulus before any manipulation (including handling) with the animal's nociceptive sensitivity after handling, anaesthesia and i.c.v. injection of OFQ, and reported that they never saw OFQ produce hyperalgesia. After the realization that OFQ can act as a functional antiopioid, i.e. reverse opioid-mediated stressinduced analgesia when given i.c.v., Mogil and colleagues hypothesized that the peptide might also reverse morphine-induced analgesia. When this hypothesis was tested using the tail-withdrawal and hotplate assays, OFQ (delivered by i.c.v. injection) dose-dependently reversed morphine-induced analgesia. Additional studies have demonstrated that OFQ can reverse analgesia after activation of mu, delta and kappa opioid receptors in the mouse. 39 Similar findings have also been reported in the rat. 56 OFQ administered i.c.v. has also been shown to dosedependently block the analgesia induced by electroacupuncture as measured in a radiant-heat tail-flick assay. 57 In addition, antisense OFQ receptor oligonucleotides potentiated analgesia by electroacupuncture, presumably by interfering with expression.
Mechanisms explaining the antagonistic effects of supraspinal OFQ on analgesia are being investigated. Although the exact brain structures responsible for these responses remain to be identified, the periaqueductal gray is an attractive candidate. The reasons for this include reports that OFQ inhibits the firing of neurones in the periaqueductal gray via both pre-and post-synaptic actions, 59 together with the observation that the peptide can have profound behavioural consequences with respect to an animal's response to morphine. 42 Another brain region that has been shown to be exquisitely sensitive to the effects of exogenous OFQ is the RVM. 22 The demonstration that OFQ potently blocks the analgesic effect of opioids when locally administered to the RVM is consistent with the peptide's ability to suppress the firing of "off-cells", a population of neurones that when disinhibited by opiates interfere with nociceptive processing in the dorsal horn of the spinal cord (reviewed in reference 17).
Spinal actions of OFQ
In contrast to its functional supraspinal, anti-opioid actions, OFQ is reported to be capable of producing analgesia when administered intrathecally (i.t.). 31 63 Using the tail-withdrawal assay as the measure of nociceptive sensitivity, Grisel and colleagues 21 demonstrated that OFQ administered i.t. in mice does not reverse morphine analgesia but rather there was a trend toward potentiating the morphine analgesia. In fats, i.t. OFQ produces significant analgesia as measured using the tail-flick assay and potentiates the analgesia produced by morphine 39 56 and electroacupuncture. 57 In addition, OFQ administered i.t. attenuated the increased nociceptive responsiveness resulting from nerve injury or inflammation. 65 In summary, anatomical distribution, electrophysiology and behavioural studies all strongly suggest that that OFQ has a role in pain modulation and nociception. Judging by the contrasting activity of OFQ in brain and spinal cord, this role clearly involves the co-ordinated activity of multiple areas of the central nervous system.
Future directions
The expression pattern of ppOFQ and its receptor, as well as the documented functional anti-opioid effects that OFQ produces in mice and rats exposea to morphine, strongly suggest that the pharmacological manipulation of this system may have important clinical applications ranging from pain management to the treatment of tolerance and dependence. Furthermore, the sheer abundance of OFQ peptide in the brain and spinal cord implies that it is a major neurotransmitter, on a par with the opioid peptides and the biogenic amines dopamine, noradrenaline and serotonin. Consequently, a better understanding of the relationship between the OFQ system and these others will help us to comprehend the neuroanatomical and neurophysiological underpinnings of many behaviours.
If we are to expand our knowledge of the role of OFQ, we must be certain about what effects are attributable to the activation of its receptor. Therefore a selective antagonist is required before we can progress much further in vivo. Equipped with such a reagent it should be possible to identify those actions that are the direct consequence of OFQ receptor activation, in addition to reconciling some of the conflicting reports about the behavioural effects of OFQ. Although there has been some progress in the identification of novel ligands with high affinity for the OFQ receptor, 13 no selective antagonists have been reported. Of course the identification of new ligands involves much effort and complex screening processes. In this regard two of the classic preparations that are still used for screening purposes are the guinea pig ileum and the mouse vas deferens. 33 34 These two smooth-muscle preparations have repeatedly proven their worth in the search for novel opioid receptor antagonists, and with reports describing OFQ effects in these two preparations 4 7 68 and the establishment of cell lines that stably express the receptor, many of the necessary screening tools are available for the identification of new OFQ-receptor ligands.
More detailed anatomical mapping of the OFQ system is also needed, and this will require the development of additional immunocytochemical reagents. Retrograde tracing and stereotaxic microinjection experiments are likely to provide important information as we attempt to define further the neuronal circuitry influenced by OFQ.
Finally, transgenic mice that lack the OFQ receptor have already revealed an unexpected role for this system in hearing, 44 and will undoubtedly provide new insights into the role of the OFQ system in other behaviours. As these animals become available to more investigators we can expect a wealth of new information about the in vivo functions of the OFQ system to emerge. It can also be anticipated that the next generation of transgenic mice will carry inducible vectors whose activation will result in the selective disruption of a target sequence, thereby avoiding the problems of interpretation that can accompany the more traditional developmental knockouts.
We are in a period of rapid discovery with respect to this major new neurotransmitter system. One of the challenges before us is to apply our expanding basic knowledge about the OFQ system to the management of pain.
